How to offer GHK-Cu at your business
Learn what GHK-Cu is, where it stands with the FDA today, and how to build a clinician-led GHK-Cu offering.
This content is for general informational purposes only. It is not medical or legal advice and does not create a clinician-patient or attorney-client relationship. For guidance on your specific situation, consult a licensed clinician or attorney.
GHK-Cu has a compounding pathway, but it isn’t the one most operators have likely been reading about.
When the U.S. Department of Health and Human Services (HHS) released a draft interim enforcement discretion policy for six peptides on October 28, 2026, GHK-Cu wasn’t one of them. Non-injectable GHK-Cu already sits in the FDA’s Category 1 under the agency’s existing interim policy for 503A compounding. Injectable GHK-Cu is excluded.
The distinction matters. Many patients already know about GHK-Cu, a copper based peptide, with associations with skincare, at a time when demand for aesthetics and skin health services is on the rise. Getting the route and sourcing rules right is what separates a clinical offering from a risky one.
This guide covers how to offer GHK-Cu at your business: what the peptide is, where it stands with the FDA, and seven steps to build a clinician-led offering.
What is GHK-Cu?
GHK-Cu is a complex of copper and the three-amino-acid peptide GHK (glycyl-L-histidyl-L-lysine), which occurs naturally in human plasma.²³ It is also used as an ingredient in cosmetic products.²⁴
What the research shows
Laboratory and animal research, summarized in narrative reviews, has examined GHK-Cu’s role in processes such as collagen synthesis and tissue repair.²³,²⁴ Most human research concerns topical use in dermatology. Evidence for injectable use is more limited, and narrative reviews are not a substitute for controlled clinical trials of compounded products.
Why businesses are adding GHK-Cu
Peptides have grown in demand the last few years in parallel with the growing patient interest in more comprehensive, whole health care.
Google searches for the term “peptides” rose 398% year over year from June 2025 to July 2026, and the global peptide therapeutics market is projected to grow from $140.86 billion in 2025 to $294.58 billion by 2033.
Is GHK-Cu legal to offer?
Non-injectable GHK-Cu can be compounded by 503A pharmacies under the FDA’s existing interim policy, but only within specific limits. Here’s what operators need to know:
- Topical GHK-Cu is in Category 1. It appears on the FDA’s current Category 1 list and falls within the agency’s interim enforcement policy for 503A compounding only when all of the guidance’s conditions are met.
- Injectable GHK-Cu is excluded. The FDA’s list names “GHK-Cu (except for injectable routes of administration).”
- GHK-Cu is not part of HHS’s interim policy for six peptides. That October 2026 policy is a separate framework with its own conditions. See our breakdown of the six peptides included in the HHS interim compounding pathway
- Category 1 status is not FDA approval. It also isn’t the same as formal inclusion on the 503A Bulks List. The FDA has said it intends to consult the Pharmacy Compounding Advisory Committee (PCAC) about GHK-Cu before the end of February 2027, which could change its status.
- State requirements still apply. Federal policy sits on top of state pharmacy, prescribing, and scope-of-practice rules, not in place of them.
For a better understanding of the different categories used to classify peptides, read our guide.
What forms of GHK-Cu can be compounded?
Route is the aspect that matters most. Here’s how the rules stand today:
- Topical routes only. Topical preparations are the most common example.
- No injectable GHK-Cu. That includes in-clinic administration and any framing that positions injection as a separate service.
- Cosmetics are a separate category. Over-the-counter skincare products containing copper peptides are regulated differently from compounded prescription drugs. A compounded GHK-Cu preparation is legally considered a prescription drug, and your program should treat it as one.
How to offer GHK-Cu at your business
The seven steps below walk through what it takes to launch a clinical GHK-Cu offering. If you’re planning a broader program, our guide on how to offer a peptide therapy program at your business covers it in a bit more detail.
- Decide where GHK-Cu fits
- Choose your delivery model
- Build the clinical and regulatory foundation
- Vet your pharmacy partner(s)
- Standardize the patient journey
- Set up the technology
- Plan for policy changes
1. Decide where GHK-Cu fits
Start with your existing services and patient population. Does a non-injectable GHK-Cu offering fit your focus? Are your patients already asking for it?
Consider these things:
- Patient demand in your current population
- Clinical capacity to evaluate and follow patients
- Fit with your brand and existing services
Every decision should come back to the benefit and safety of your patients.
2. Choose your care delivery model
Decide whether to offer GHK-Cu in person, virtually, or through a hybrid model.
What you choose also determines certain regulatory restrictions. For instance, multi-state virtual care requires a provider in each state and alignment to that state’s compounding policies. Also, certain states may have different compounding laws and regulations.
Because only non-injectable forms are eligible, there’s no administration visit to plan around, and topical preparations ship well. That makes virtual and hybrid models practical:
- Virtual: Requires clear application instructions, a simple way for patients to share questions or concerns, and timely clinician follow-up
- In person or hybrid: Typically consists of in-clinic consultations and skin assessments, with ongoing follow-up handled virtually
3. Build the clinical and regulatory foundation
Before accepting patients, establish who is responsible for clinical decisions and how the program will operate.
At a minimum, define:
- Which licensed clinicians can evaluate patients and prescribe
- Do you have the provider capacity to support this program
- How the pharmacy receives a valid, patient-specific prescription
- How clinical rationale and prescribing decisions are documented
- Which supervision and practice requirements apply in each state
- How patient eligibility, consent, follow-up, and escalation are handled
Prescription of a peptide is always under the discretion and clinical judgment of the provider based on patient health and data.
4. Vet your pharmacy partner
Your pharmacy partner determines whether your product complies with the FDA’s interim policy.
If you’re new to how these pharmacies operate, start with our overview of 503A compounding pharmacies. Then confirm that every partner:
- Is a state-licensed 503A pharmacy
- Compounds non-injectable GHK-Cu formulations only
- Sources bulk substance from an FDA-registered establishment, with a valid certificate of analysis (CoA)
- Meets quality standards appropriate to the preparation, such as USP 795 for nonsterile compounding (confirm with your partner)
- Is licensed in every state you ship to
Research-use-only peptides can never be used, regardless of price or availability.
Step 5: Standardize the patient journey, with clinicians at the center
Map the experience from the first inquiry through follow-up. Patients should understand what the product is, what is known about the research, and what the limitations are.
Build a consistent process for:
- Intake and clinical evaluation
- Informed consent
- Prescription and dispensing coordination
- Patient instructions and follow-up
- Reporting and escalation if a patient experiences a side effect or has a product quality concern
Give patients clear instructions for contacting your team. Define who reviews a report, when the prescribing clinician gets involved, and how serious concerns are escalated.
6. Set up the technology
Your tech stack should connect intake, clinical documentation, patient messaging, lab and pharmacy coordination, and follow-up in one workflow. Ensure all systems and patient data are secure and protected.
If you’d rather not assemble that yourself, a white-label platform like OpenLoop® lets you run pre-built clinical infrastructure under your brand.
7. Plan for policy changes
The FDA plans to consult PCAC about injectable GHK-Cu before the end of February 2027, and its status could change in either direction.
Build change management into your program from day one:
- Monitor the FDA’s Category 1 list and PCAC announcements
- Track any formal 503A Bulks List rulemaking for GHK-Cu
- Have a continuity plan for patients if GHK-Cu’s status narrows or expands, including how you’ll communicate changes
Work through these seven steps in order, and you’ll have a GHK-Cu offering that fits your existing services, stays within the FDA’s route restrictions, and can adapt as federal guidance evolves.
Add GHK-Cu to your business with OpenLoop
Building a peptide program takes more than finding a pharmacy. It also depends on having the right clinicians and clinical processes in place. OpenLoop® offers infrastructure to help businesses develop and operate peptide services, including:
- 503A pharmacy partners where permitted by law
- Medically reviewed protocols
- A 50-state clinician network
- Compliance-aligned infrastructure
- 24/7/365 patient support
Contact OpenLoop to discuss your business and program needs.
Compounded drugs are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality. The peptides discussed in this article have not been approved by FDA for recovery or performance. Compounded preparations require a prescription following an appropriate clinical evaluation, and no prescription is guaranteed. Availability varies based on clinical appropriateness, applicable federal and state laws, pharmacy availability, and other regulatory requirements. Not all peptide therapies are available in all states or through all pharmacies.
